Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Benjamin J Huang, Lauren K. Meyer, Adam Lamble, Jim Wang, Rhonda E Ries, Alan S Gamis, Richard Aplenc, Katherine Tarlock, Todd Cooper, E. Anders Kolb, Todd A. Alonzo, Soheil Meshinchi, Joseph Chewning, William G. Woods, John T. Horan

Blood (2023) 142 (Supplement 1): 655.

https://doi.org/10.1182/blood-2023-186955

Published: 2023

Journal Articles

Integrated Methylation and Transcriptional Landscape and Evolution of Pediatric AML

Benjamin J Huang, Hamid Bolouri, Colin Y. Smith, Jim Wang, Rhonda E Ries, Elizabeth Conran, Alan S Gamis, Richard Aplenc, Todd A. Alonzo, Xiaotu Ma, Timothy Junius Triche, Jason E Farrar, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 2956.

https://doi.org/10.1182/blood-2023-187819

Published: 2023

Journal Articles

DNMT3A Mutants Are Enriched in NPMc+ AML and Associated with Adverse Outcome in Childhood AML

Rhonda E Ries, Xiaotu Ma, Claudia Tregnago, Todd A. Alonzo, Jim Wang, Tiffany Hylkema, Benjamin J Huang, Alireza Torabi, Jack H Peplinski, Logan K Wallace, Richard Aplenc, Alan S Gamis, Katherine Tarlock, Franco Locatelli, Martina Pigazzi, Soheil Meshinchi

Blood (2023) 142 (Supplement 1): 4306.

https://doi.org/10.1182/blood-2023-181060

Published: 2023

Journal Articles

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Richard J Marrero, Vivek M. Shastri, Richard Aplenc, Todd Cooper, Todd A. Alonzo, Alan S Gamis, Jim Wang, Soheil Meshinchi, E. Anders Kolb, Jatinder K. Lamba

Blood (2023) 142 (Supplement 1): 4314.

https://doi.org/10.1182/blood-2023-187515

Published: 2023

Journal Articles

Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A -Rearranged RAS Pathway-Mutant Acute Leukemia

Nastassja Scheidegger, Gabriela Alexe, Delan Khalid, Rhonda E Ries, Jim Wang, Todd A. Alonzo, Jennifer Perry, Scott A Armstrong, Soheil Meshinchi, Yana Pikman, Kimberly Stegmaier

Blood (2023) 142 (Supplement 1): 166.

https://doi.org/10.1182/blood-2023-185561

Published: 2023

Journal Articles

Β-Lactam Antibiotic Ceftriaxone As a Potential Therapeutic Intervention for Chronic Pain in Sickle Cell Disease

Ying He, Xiao Guo, Robert Molokie, Zaijie Jim Wang

Blood (2023) 142 (Supplement 1): 2495.

https://doi.org/10.1182/blood-2023-188342

Published: 2023

Journal Articles

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Michele S. Redell, Todd A. Alonzo, Robert Gerbing, Jim Wang, Maureen M. O'Brien, Gwen Nichols, Laura Di Laurenzio, Sarah K. Tasian, C. Michel Zwaan, Dirk Reinhardt, E. Anders Kolb, Todd Cooper

Blood (2023) 142 (Supplement 1): 1492.

https://doi.org/10.1182/blood-2023-190947

Published: 2023

Journal Articles

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Adam J. Lamble, MD, Lisa Eidenschink Brodersen, PhD, Todd A. Alonzo, PhD, Jim Wang, Robert B. Gerbing, Laura Pardo, Lillian Sung, MD PhD, Sarah K. Tasian, MD, Todd M Cooper, DO, E. Anders Kolb, MD, Richard Aplenc, MD PhD, Michael R. Loken, PhD, Soheil Meshinchi, MD PhD

Blood (2019) 134 (Supplement_1): 459.

https://doi.org/10.1182/blood-2019-124587

Published: 2019

Journal Articles

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

Lata Chauhan, PhD, Todd A Alonzo, PhD, Jim Wang, Michael R. Loken, PhD, Jessica A. Pollard, MD, Richard Aplenc, MD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Betsy A Hirsch, PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Soheil Meshinchi, MD PhD, Jatinder Lamba, PhD

Blood (2017) 130 (Supplement 1): 2526.

https://doi.org/10.1182/blood.V130.Suppl_1.2526.2526

Published: 2017

Journal Articles

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Jatinder Lamba, PhD, Lata Chauhan, PhD, Miyoung Shin, PhD, Michael R. Loken, PhD, Jessica A. Pollard, MD, Jim Wang, Richard Aplenc, MD, Betsy A Hirsch, PhD, Susana C. Raimondi, PhD, Roland B. Walter, MD PhD, Irwin D. Bernstein, MD, Alan S Gamis, MD MPH, Todd A Alonzo, PhD, Soheil Meshinchi, MD PhD

Blood (2017) 130 (Supplement 1): 3826.

https://doi.org/10.1182/blood.V130.Suppl_1.3826.3826

Published: 2017

Journal Articles

Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531

Erin M. Guest, Richard Aplenc, Lillian Sung, Susana C. Raimondi, Betsy A. Hirsch, Todd A. Alonzo, Robert B. Gerbing, Yi-Cheng Jim Wang, Samir B. Kahwash, Amy Heerema-McKenney, Soheil Meshinchi, Alan S. Gamis

Blood (2017) 130 (7): 943–945.

https://doi.org/10.1182/blood-2017-01-762336

Published: 2017

Includes: Supplemental data

Journal Articles

A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia

Emilia L. Lim, PhD, Diane L. Trinh, MSc, Rhonda E. Ries, MA, Jim Wang, Yussanne Ma, PhD, James Topham, Maya D. Hughes, MD, Erin Pleasance, PhD, Andrew J. Mungall, Richard Moore, PhD, Yongjun Zhao, PhD, E. Anders Kolb, MD, Alan S. Gamis, MD MPH, Daniela S. Gerhard, PhD, Todd A. Alonzo, PhD, Soheil Meshinchi, MD PhD, Marco A. Marra, PhD

Blood (2016) 128 (22): 1210.

https://doi.org/10.1182/blood.V128.22.1210.1210

Published: 2016

Journal Articles

Validation of Pain report it Neuropathic Pain Scale in African American Adults with Sickle Cell Disease

Keesha Roach, RN, MS, Robert E Molokie, MD, Zaijie Jim Wang, PhD, Mariam O Ezenwa, PhD, David Shuey, BA, Jesus Carrasco, BA, Veronica Angulo, BS, Judith Schlaeger, PhD, Marie L Suarez, PhD, Yingwei Yao, PhD, Diana J Wilkie, PhD

Blood (2016) 128 (22): 3525.

https://doi.org/10.1182/blood.V128.22.3525.3525

Published: 2016

Journal Articles

Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531

Keith J. August, MD MS, Richard Aplenc, MD PhD, Lillian Sung, MD PhD, Susana C. Raimondi, PhD, Betsy A. Hirsch, PhD, John T. Horan, MD MPH, Todd A. Alonzo, PhD, Robert B. Gerbing, MA, Yi-Cheng Jim Wang, MS, Samir Kahwash, MD, Amy Heerema-McKenney, MD, Soheil Meshinchi, MD PhD, Alan S. Gamis, MD MPH

Blood (2014) 124 (21): 3672.

https://doi.org/10.1182/blood.V124.21.3672.3672

Published: 2014

Journal Articles

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Hagop M. Kantarjian, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Andreas Hochhaus, MD, Jerald P. Radich, MD, Giuseppe Saglio, MD, Timothy P. Hughes, MD, MBBS, Giovanni Martinelli, MD, Dong-Wook Kim, MD, PhD, Yaping Shou, MD, PhD, Neil J. Gallagher, MD, PhD, Jim Wang, PhD, Jorge Cortes-Franco, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD

Blood (2009) 114 (22): 1129.

https://doi.org/10.1182/blood.V114.22.1129.1129

Published: 2009

Journal Articles

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Bernadeta Ceglarek, Anna Turkina, Dong-Wook Kim, MD, PhD, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Ellison Dial, MBA, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 1115.

https://doi.org/10.1182/blood.V114.22.1115.1115

Published: 2009

Journal Articles

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Blood (2009) 114 (22): 3293.

https://doi.org/10.1182/blood.V114.22.3293.3293

Published: 2009

Journal Articles

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Hagop M. Kantarjian, MD, Elias Jabbour, MD, Francis J. Giles, MB, MD, FRCPI, FRCPath, Kapil N. Bhalla, MD, Javier Pinilla-Ibarz, MD, PhD, Richard A. Larson, MD, Norbert Gattermann, MD, PhD, Oliver G. Ottmann, MD, Jim Wang, PhD, Richard C. Woodman, MD, Michele Baccarani, MD, Philipp D. le Coutre, MD, Jorge Cortes, MD

Blood (2009) 114 (22): 3298.

https://doi.org/10.1182/blood.V114.22.3298.3298

Published: 2009

Journal Articles

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Philipp D. le Coutre, MD, Anna Turkina, Dong-Wook Kim, MD, PhD, Bernadeta Ceglarek, Giuliana Alimena, Haifa Kathrin Al-Ali, MD, Zhixiang Shen, Saengsuree Jootar, MD, Graeme Smith, MD, Carmino Antonio De Souza, MD, PhD, Pedro Enrique Dorlhiac-Llacer, David A Rizzieri, MD, Tomasz Szczudlo, MD, Myriam Berton, Jim Wang, PhD, Si-Tien Wang, Franck Emmanuel Nicolini, MD, PhD

Blood (2009) 114 (22): 3286.

https://doi.org/10.1182/blood.V114.22.3286.3286

Published: 2009

Journal Articles

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Ricardo Pasquini, MD, Jorge Cortes-Franco, MD, Hagop M. Kantarjian, MD, David Joske, MBBS, FRCPA, FRACP, Zhixiang Shen, MD, PhD, Luis Meillon, MD, Lidia Mongay, MD, PhD, MBA, Dawn F. Eng, Jim Wang, PhD, Timothy P. Hughes, MD, MBBS, Dong-Wook Kim, MD, PhD

Blood (2009) 114 (22): 4267.

https://doi.org/10.1182/blood.V114.22.4267.4267

Published: 2009

NARROW

Impact of Molecular Risk on Efficacy of Blood and Marrow Transplantation for Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Integrated Methylation and Transcriptional Landscape and Evolution of Pediatric AML

DNMT3A Mutants Are Enriched in NPMc+ AML and Associated with Adverse Outcome in Childhood AML

ACS10- Cytarabine Pharmacogenomics Score Impacts Survival in Pediatric AML Patients Treated on AAML1031 Trial and Associates with Outcome Differences in Black AML Patients

Combining Menin and MEK Inhibition to Target Poor Prognostic KMT2A -Rearranged RAS Pathway-Mutant Acute Leukemia

Β-Lactam Antibiotic Ceftriaxone As a Potential Therapeutic Intervention for Chronic Pain in Sickle Cell Disease

APAL2020SC Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias

Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group

Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children's Oncology Group AAML0531 Trial

CD33-Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children's Oncology Group AAML0531 Trial

Gemtuzumab ozogamicin in infants with AML: results from the Children’s Oncology Group trials AAML03P1 and AAML0531

A microRNA Expression-Based Model Predicts Event Free Survival in Pediatric Acute Myeloid Leukemia

Validation of Pain report it Neuropathic Pain Scale in African American Adults with Sickle Cell Disease

Adolescents and Young Adults (AYA) with Acute Myeloid Leukemia (AML) Have Increased Treatment-Related Mortality with Similar Outcomes -- a Report from the Children's Oncology Group Trials AAML03P1 and AAML0531

Update On Imatinib-Resistant Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) On Nilotinib Therapy at 24 Months: Clinical Response, Safety, and Long-Term Outcomes.

Patterns and Management of Selected Adverse Events of Adult Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia (CML) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Prognostic Factors for Progression-Free Survival in Patients with Imatinib-Resistant or -Intolerant Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Nilotinib Based On 24 Month Data.

Efficacy and Safety of Nilotinib in Elderly Patients with Imatinib-Resistant or -;Intolerant Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A Sub-Analysis of the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

A Worldwide Observational Registry Collecting Longitudinal Data On the Management of CML Patients (The WORLD CML Registry) - Summary of the First 1001 Patients.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only